Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
GLP-1-based therapies showed a notable rebound, likely due to the loss of metabolic and appetite-suppressing effects after treatment cessation
Strong dual CYP3A4/P-gp inhibitors (ketoconazole, ritonavir, clarithromycin) can double apixaban exposure [1]
Final approval of the manuscript: I.K.J., S.W.K
In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided
US$ 20.72
US$ 29.05
US$ 22.55
US$ 29.02
US$ 26.62
US$ 24.81
.webp)
US$ 21.80
